- Home
- OMGA vs HOWL Comparison
OMGA vs HOWL Comparison
Compare OMGA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMGA
- HOWL
- Stock Information
- Founded
- OMGA 2017
- HOWL 2017
- Country
- OMGA United States
- HOWL United States
- Employees
- OMGA N/A
- HOWL N/A
- Industry
- OMGA Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- OMGA Health Care
- HOWL Health Care
- Exchange
- OMGA Nasdaq
- HOWL Nasdaq
- Market Cap
- OMGA 74.5M
- HOWL 87.4M
- IPO Year
- OMGA 2021
- HOWL 2021
- Fundamental
- Price
- OMGA $0.98
- HOWL $1.93
- Analyst Decision
- OMGA Strong Buy
- HOWL Strong Buy
- Analyst Count
- OMGA 5
- HOWL 2
- Target Price
- OMGA $10.20
- HOWL $13.50
- AVG Volume (30 Days)
- OMGA 399.1K
- HOWL 1.7M
- Earning Date
- OMGA 11-19-2024
- HOWL 11-07-2024
- Dividend Yield
- OMGA N/A
- HOWL N/A
- EPS Growth
- OMGA N/A
- HOWL N/A
- EPS
- OMGA N/A
- HOWL N/A
- Revenue
- OMGA $6,314,000.00
- HOWL $3,386,000.00
- Revenue This Year
- OMGA $127.25
- HOWL N/A
- Revenue Next Year
- OMGA N/A
- HOWL $191.98
- P/E Ratio
- OMGA N/A
- HOWL N/A
- Revenue Growth
- OMGA 142.47
- HOWL N/A
- 52 Week Low
- OMGA $0.89
- HOWL $1.66
- 52 Week High
- OMGA $6.30
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- OMGA 40.48
- HOWL 38.11
- Support Level
- OMGA $1.06
- HOWL $2.19
- Resistance Level
- OMGA $1.17
- HOWL $2.24
- Average True Range (ATR)
- OMGA 0.11
- HOWL 0.20
- MACD
- OMGA -0.01
- HOWL -0.09
- Stochastic Oscillator
- OMGA 2.44
- HOWL 1.65
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.